Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Lite Strategy Inc. | Pracinostat in combination with Vidaza | High-risk Myelodysplastic Syndrome (MDS) | Phase 2 | Trial Discontinued | Oral | Hematology |
| Lixte Biotechnology Holdings Inc. | LB-100 | Glioblastoma Multiforme | Phase 2 | Ongoing | Intravenous | Oncology |
| Longboard Pharmaceuticals Inc. | Bexicaserin (LP352) - (DEEp OCEAN) | Adolescent and adult patients with developmental and epileptic encephalopathies (DEEs) | Phase 3 | Ongoing | Oral | Neurology |
| Longboard Pharmaceuticals Inc. | Bexicaserin (LP352) - (DEEp SEA) | Dravet Syndrome | Phase 3 | Enrollment Initiation | Oral | Neurology |
| Longeveron Inc. | Laromestrocel (lomecel-B) - (CLEAR MIND) | Alzheimer's Disease | Phase 2/3 | Trial Planned | Intravenous infusion | Neurology |
| Longeveron Inc. | Laromestrocel (lomecel-B) - (ELPIS II) | Hypoplastic Left Heart Syndrome | Phase 2b | Data Released | Intravenous | Cardiology |
| Longeveron Inc. | Laromestrocel (lomecel-B) | Metabolic Syndrome | Phase 2b | Ongoing | Intravenous | Endocrinology |
| Longeveron Inc. | Laromestrocel (lomecel-B) | Aging Frailty | Phase 2b | Ongoing | Intravenous | N/A |
